Oscar Health downgraded to Sell on exchange uncertainty, sees 30% enrollment hit

UBS downgraded Oscar Health to Sell from Neutral, cutting its price target to $11 from $15, citing growing instability within Affordable Care Act (ACA) exchanges that is not fully priced into the stock. The brokerage now forecasts a sharper 30% decline in Oscar's 2026 exchange enrollment, worsening from a prior 18% estimate, primarily due to expiring federal subsidies and limited ability to offset with pricing. This, combined with broader industry headwinds like higher-than-expected utilization and tightening federal oversight, leads UBS to project lower 2027 revenue and EPS for Oscar, indicating a 'murky' margin outlook and making share support challenging without a more stable policy and pricing environment.

Analysis

UBS has downgraded Oscar Health (OSCR) to Sell from Neutral, cutting its price target to $11 from $15, citing growing instability within the Affordable Care Act (ACA) exchanges that it believes is not fully priced into the stock. The downgrade is underpinned by a significantly worsened forecast for Oscar's 2026 exchange enrollment, which UBS now expects to decline by 30%—a sharp revision from its prior 18% estimate—due to the expiration of enhanced federal subsidies. The analysis suggests Oscar possesses limited pricing power to offset this, projecting only a 25% recovery from price adjustments. This specific headwind is amplified by broader industry pressures, evidenced by Centene (CNC) withdrawing its full-year guidance and other insurers like Elevance (ELV) and Molina (MOH) flagging higher-than-expected utilization. Consequently, UBS projects Oscar's 2027 revenue at $12.2 billion and EPS at $1.25, below the consensus EPS of $1.46, highlighting an "increasingly murky" margin outlook. The instability is further underscored by CVS's market exit and the 6 million Americans at risk of losing coverage, making the overall market "difficult to calibrate" and challenging Oscar's valuation.

Key Decisions for Investors

• Given the sell rating and a material downward revision in enrollment forecasts, investors should reassess positions in Oscar Health due to significant downside risk from both regulatory catalysts and pricing pressure.
• The sector-wide issues, including Centene pulling guidance and peers flagging higher utilization, suggest applying increased scrutiny to other health insurers with high exposure to the ACA marketplace.
• Investors should closely monitor Oscar's upcoming quarterly results for any deterioration in its medical loss ratio and management's commentary on member retention, which will be the earliest indicators of these forecasted headwinds.
• The investment thesis is heavily tied to US policy; any legislative developments regarding the extension of federal ACA subsidies beyond 2025 would be a critical, potentially thesis-altering, catalyst to watch.